Insider Transactions in Q4 2025 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,980
-4.22%
|
$199,200
$40.0 P/Share
|
|
Dec 24
2025
|
William E. Rote Chief Research Officer |
SELL
Open market or private sale
|
Direct |
60,000
-37.16%
|
$2,400,000
$40.1 P/Share
|
|
Dec 24
2025
|
William E. Rote Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+27.1%
|
$1,200,000
$20.61 P/Share
|
|
Dec 24
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-14.45%
|
$630,000
$42.0 P/Share
|
|
Dec 24
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.63%
|
$120,000
$8.93 P/Share
|
|
Dec 24
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
7,402
-16.22%
|
$296,080
$40.0 P/Share
|
|
Dec 15
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
2,910
-5.99%
|
$104,760
$36.0 P/Share
|
|
Dec 01
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
20,000
-17.84%
|
$700,000
$35.01 P/Share
|
|
Dec 01
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+15.14%
|
$320,000
$16.23 P/Share
|
|
Nov 04
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
67,115
-58.03%
|
$2,416,140
$36.0 P/Share
|
|
Nov 04
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
61,250
+11.97%
|
$1,347,500
$22.19 P/Share
|
|
Nov 03
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Bona fide gift
|
Direct |
1,078
-0.91%
|
-
|
|
Oct 31
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,591
-4.48%
|
$195,685
$35.0 P/Share
|
|
Oct 31
2025
|
Timothy Coughlin |
SELL
Open market or private sale
|
Direct |
18,000
-24.49%
|
$630,000
$35.03 P/Share
|
|
Oct 31
2025
|
Timothy Coughlin |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+11.58%
|
$288,000
$16.89 P/Share
|
|
Oct 29
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
27,128
-6.08%
|
$813,840
$30.12 P/Share
|
|
Oct 29
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
27,128
+5.73%
|
$406,920
$15.46 P/Share
|
|
Oct 28
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,662
-2.09%
|
$79,860
$30.0 P/Share
|
|
Oct 28
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
92,872
-18.14%
|
$2,786,160
$30.38 P/Share
|
|
Oct 28
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
92,872
+15.35%
|
$1,393,080
$15.46 P/Share
|